Evoke Pharma, Inc. (NASDAQ:EVOK) has been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.20.

Several research analysts have issued reports on the stock. ValuEngine downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Evoke Pharma in a research report on Tuesday, August 15th.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/evoke-pharma-inc-evok-receives-average-rating-of-hold-from-analysts.html.

Large investors have recently modified their holdings of the company. State Treasurer State of Michigan boosted its holdings in shares of Evoke Pharma by 62.2% in the first quarter. State Treasurer State of Michigan now owns 291,966 shares of the specialty pharmaceutical company’s stock valued at $905,000 after acquiring an additional 111,966 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after acquiring an additional 68,544 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Evoke Pharma in the first quarter valued at about $1,550,000. 12.88% of the stock is currently owned by institutional investors and hedge funds.

Evoke Pharma (NASDAQ EVOK) traded down 2.65% on Friday, reaching $3.31. 335,880 shares of the company were exchanged. The stock has a 50-day moving average price of $2.56 and a 200 day moving average price of $2.69. The stock’s market capitalization is $50.93 million. Evoke Pharma has a 52 week low of $1.35 and a 52 week high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.15). During the same period in the prior year, the firm earned ($0.41) EPS. Analysts forecast that Evoke Pharma will post ($0.94) earnings per share for the current year.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.